Mosaic ImmunoEngineering Inc. (CPMV) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US61945M1018
Mosaic ImmunoEngineering Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -616,119.00 USD |
| EBIT | -675,445.00 USD |
| Net income | -687,846.00 USD |
| Diluted EPS – continuing operations | -0.10 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. The company engages in pursuing new product candidates and platforms to build a pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.
More stocks
- Mitesco, Inc. (MITI)
- Green Planet Bio Engineering Co. Ltd. (GPLB)
- Greenlane Holdings, Inc. (GNLN)
- Leslie's, Inc. (LESL)
- Target Group Inc. (CBDY)
- GOOD GAMING, INC. (GMER)
- CANNABIS SUISSE CORP. (CSUI)
- Cyber Enviro-Tech, Inc. (CETI)
- SpringBig Holdings, Inc. (SBIG)
- ALPHA MODUS HOLDINGS, INC. (AMOD)
- Evofem Biosciences, Inc. (EVFM)
- Tradewinds Universal (TRWD)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.